Highlights

• The Journal of Hospital Infection has published results from a Steriwave study at the University of Ottawa Heart Institute.

• Conduit-harvest surgical site infections fell from 3.6% to 1.7%, representing a reported 52.8% relative reduction.

• Researchers tracked 2,172 coronary artery bypass graft procedures across a 32-month interrupted Time Series design.

• Protocol compliance climbed from 35.4% at baseline to 93.3% once Steriwave nasal photodisinfection replaced mupirocin in practice.

What happens to infection rates when a heart hospital swaps an antibiotic nasal ointment for a light-based treatment? Ondine Biomedical (LSE:OBI) now has a peer-reviewed answer, with results from the University of Ottawa Heart Institute appearing in the Journal of Hospital Infection. The paper follows more than two thousand bypass operations and reports lower conduit-harvest infection rates alongside a sharp rise in protocol compliance.

Inside the Ottawa Study

The work was carried out at the University of Ottawa Heart Institute and examined patients undergoing coronary artery bypass graft (CABG) surgery. Its design was a non-randomised, before-and-after interrupted time series running over 32 months.

In total, 2,172 CABG procedures were included. Of these, 1,678 formed the baseline group, in which patients received mupirocin. The remaining 494 made up the intervention group, treated with Steriwave, the company's nasal photodisinfection technology.

Key study parameters at a glance:

• Setting: University of Ottawa Heart Institute

• Procedure type: coronary artery bypass graft surgery

• Duration: 32 months

• Design: non-randomised interrupted time series, before and after

• Comparator: mupirocin (1,678 procedures)

• Intervention: Steriwave nasal photodisinfection (494 procedures)

• Journal: Journal of Hospital Infection, peer-reviewed

Headline Outcome: Conduit-Harvest Infections

The lead result for Ondine Biomedical (LSE:OBI) centres on surgical site infections at the conduit-harvest site. These infections fell from 3.6% in the mupirocin group to 1.7% in the Steriwave group, which the published results describe as a 52.8% relative reduction.

Total surgical site infections across all sites moved from 9.1% to 5.9%. The paper notes that the secondary outcomes did not reach statistical significance. A sensitivity analysis that excluded the transition month between the two protocols also did not retain statistical significance, a detail the study sets out alongside its main findings.

Compliance Gains Across Patient Groups

Protocol adherence stands out in the data. Compliance rose from 35.4% under the mupirocin baseline to 93.3% once Steriwave was adopted.

The shift was sharper still for urgent cases. Among those patients, compliance moved from 17.5% to more than 93%, bringing urgent and overall adherence to broadly similar levels under the Steriwave protocol.

Why Publication Matters

Peer-reviewed publication places the Ottawa results in the clinical literature, where infection-control specialists and hospital decision-makers can examine the methodology and outcomes in full. For Ondine Biomedical (LSE:OBI), the paper adds a published cardiac surgery dataset to the evidence base surrounding Steriwave.

The before-and-after structure reflects a hospital moving from one decolonisation protocol to another, giving readers a view of the technology as it was used across 494 procedures in the intervention period rather than in a randomised trial setting.

Reading the Study Design

The Ottawa study used a before-and-after interrupted time series, a design in which outcomes are compared between a period under one protocol and a period under another. It was not randomised, which means patients were not assigned at random to different treatments, and the paper notes that secondary outcomes and a sensitivity analysis excluding the transition month did not retain statistical significance. Readers should therefore treat the findings as observations from a single hospital across 32 months. The compliance figures are notable: overall compliance rose from 35.4% to 93.3%, and among urgent cases from 17.5% to more than 93%.

The Journal of Hospital Infection is a peer-reviewed publication, which means the paper was reviewed by independent experts before publication. Readers following Ondine Biomedical can look for further data on Steriwave from other settings, since the Ottawa study describes a single hospital and a before-and-after comparison rather than a randomised trial. The announcement provides the headline figures, the study design and the compliance results in a single update.

The study results are described in the published paper.